|drug768||Choices and judgements Wiki||0.71|
|drug227||Angiotensin II Receptor Blockers Wiki||0.71|
|D002318||Cardiovascular Diseases NIH||0.12|
There are 2 clinical trials
It is supposed to monitor hypertensive patients who are infected or have clinical manifestations of COVID-19 for 1 month after the onset of the disease. Three groups will be considered: 1. receiving ACE inhibitors 2. receiving ARBs 3. receiving DIR.
Description: BP one week before COVID-19 infection and 3 weeks follow-up after COVID-19 onsetMeasure: BP (hypertensive efficacy) Time: through study completion, an average of 4 weeks
Description: number of patients with fever (above 37.2C)Measure: COVID-19 course Time: through study completion, an average of 3 weeks
Description: number of patients with coughMeasure: Cough in COVID-19 course Time: 12 weeks
Description: number of patients with throat painMeasure: Throat pain in COVID-19 course Time: 2 weeks
Description: number of patients with diarrheaMeasure: Diarrhea inf COVID-19 course Time: 2 weeks
Description: number of patients who need hospital and intensive care unitMeasure: Need to apply to hospital in COVID-19 course Time: 24 weeks
The COVID-RASi study is an international randomized clinical trial that will evaluate the potential benefit of angiotensin modulators on clinical outcomes, in older COVID-19 patients who are at high-risk for cardiovascular disease. The purpose of this study is to determine if renin-angiotensin system inhibitors (RASi), with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB), has a beneficial effect in high-risk older patients with COVID-19 infections, by reducing ICU admission, ventilator requirement or death. We would also like to determine if there are differences between ACEi and ARB therapeutic treatments.
Description: Within first 28 days post randomizationMeasure: Death Time: 28 days
Description: Within first 28 days post randomizationMeasure: Mechanical ventilation Time: 28 days
Description: Within first 28 days post randomizationMeasure: ICU admission Time: 28 days
Description: Within first 28 days post randomizationMeasure: Major Adverse Cardiac Events (MACE) Time: 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports